Genscript Biotech's share capital grows by 220,000 units

Genscript Biotech Corporation announced a significant movement in its issued share capital for the month ended September 30, 2025. The company's total number of issued ordinary shares increased by 220,000 to 2,185,319,939 shares. This rise was primarily attributed to the exercise of Post-IPO Share Option Scheme options.

The exercise of these options resulted in 220,000 new shares being issued, increasing the total funds raised during the month from the exercise of options to HK$870,360. As of the end of September 2025, the number of share options outstanding under the Post-IPO Share Option Scheme stood at 26,970,294, with 205,403,242 shares remaining available for future issuance upon exercise of all granted options under the scheme.

The company's authorised/registered share capital remains constant at 5,000,000,000 ordinary shares with a par value of $0.001 per share, totaling $5,000,000. These movements reflect ongoing activity within the company's equity structure, as detailed in its monthly return to Hong Kong Exchanges and Clearing Limited.